These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26264279)

  • 1. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
    Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
    Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.
    Shang Z; Li Y; Hsu I; Zhang M; Tian J; Wen S; Han R; Messing EM; Chang C; Niu Y; Yeh S
    Oncotarget; 2016 May; 7(19):27325-35. PubMed ID: 27092883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
    Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASC-J9
    Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
    Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor (AR) degradation enhancer ASC-J9
    Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
    Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
    EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
    Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
    Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
    Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.
    Kamat AM; Tharakan ST; Sung B; Aggarwal BB
    Cancer Res; 2009 Dec; 69(23):8958-66. PubMed ID: 19903839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases.
    Hu H; Zhou H; Xu D
    Chem Biol Drug Des; 2021 Apr; 97(4):821-835. PubMed ID: 33277796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting androgen receptor with ASC-J9 attenuates cardiac injury and dysfunction in experimental autoimmune myocarditis by reducing M1-like macrophage.
    Ma W; Wang Y; Lu S; Yan L; Hu F; Wang Z
    Biochem Biophys Res Commun; 2017 Apr; 485(4):746-752. PubMed ID: 28246012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.
    Mizushima T; Jiang G; Kawahara T; Li P; Han B; Inoue S; Ide H; Kato I; Jalalizadeh M; Miyagi E; Fukuda M; Reis LO; Miyamoto H
    Mol Cancer Ther; 2020 Sep; 19(9):1930-1942. PubMed ID: 32737155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
    Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.
    Chen F; Langenstroer P; Zhang G; Iwamoto Y; See W
    J Urol; 2003 Nov; 170(5):2009-13. PubMed ID: 14532843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
    Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C
    J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promotion of bladder cancer development and progression by androgen receptor signals.
    Miyamoto H; Yang Z; Chen YT; Ishiguro H; Uemura H; Kubota Y; Nagashima Y; Chang YJ; Hu YC; Tsai MY; Yeh S; Messing EM; Chang C
    J Natl Cancer Inst; 2007 Apr; 99(7):558-68. PubMed ID: 17406000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
    Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
    Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.